Finally, in a recent phase Ib trial, the combination of imatinib and binimetinib has shown encouraging activity in SDH-deficient GIST cohort, suggesting a potential role of targeting the ICC/GIST lineage-specific survival transcription factor, ETV1 [52]. The gene discussed is SDHB; the disease is gastrointestinal stromal tumor.